NZ332946A - Modified forms of interleukin-5 molecules capable of antagonising of IL-5 - Google Patents

Modified forms of interleukin-5 molecules capable of antagonising of IL-5

Info

Publication number
NZ332946A
NZ332946A NZ332946A NZ33294697A NZ332946A NZ 332946 A NZ332946 A NZ 332946A NZ 332946 A NZ332946 A NZ 332946A NZ 33294697 A NZ33294697 A NZ 33294697A NZ 332946 A NZ332946 A NZ 332946A
Authority
NZ
New Zealand
Prior art keywords
modified
amino acid
leu
thr
interleukin
Prior art date
Application number
NZ332946A
Inventor
Angel Lopez
Matthew Vadas
Frances Shannon
Stan Bastiras
Allan William Hey
Original Assignee
Medvet Science Pty Ltd
Bresagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medvet Science Pty Ltd, Bresagen Ltd filed Critical Medvet Science Pty Ltd
Publication of NZ332946A publication Critical patent/NZ332946A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Certain exposed acidic amino acids in a first alpha-helix of the modified interleukin-5 (IL-5) molecules are substituted with basic amino acid residues. The modified IL5 is glycosylated and the amino acid sequence comprises: Thr Ser Ala Leu Val Lys Xaa Thr Leu Ala Leu Leu Ser Thr His Arg Thr Leu Leu Ile Ala wherein Xaa is a basic or non-acidic amino acid selected from Arg, Lys, and Asn. The modified forms of IL-5 are antagonists of IL-5 and can be used in ameliorating, abating or otherwise reducing the aberrant effects caused by native or mutant forms of IL-5. Specifically, the modified form of IL-5 may be used in the treatment of allergies, myeloid leukemia, idiopathic eosinophilic syndrome, allergic inflammation, asthma and rhinitis.
NZ332946A 1996-05-24 1997-05-23 Modified forms of interleukin-5 molecules capable of antagonising of IL-5 NZ332946A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO0054A AUPO005496A0 (en) 1996-05-24 1996-05-24 An interleukin-5 antagonist
PCT/AU1997/000322 WO1997045448A1 (en) 1996-05-24 1997-05-23 An interleukin-5 antagonist

Publications (1)

Publication Number Publication Date
NZ332946A true NZ332946A (en) 2000-08-25

Family

ID=3794368

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ332946A NZ332946A (en) 1996-05-24 1997-05-23 Modified forms of interleukin-5 molecules capable of antagonising of IL-5

Country Status (6)

Country Link
EP (1) EP0904293A4 (en)
JP (1) JP2001511641A (en)
AU (1) AUPO005496A0 (en)
CA (1) CA2256368A1 (en)
NZ (1) NZ332946A (en)
WO (1) WO1997045448A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200100552A (en) 1999-04-23 2002-12-16 Pharmexa A/S A method of suppressing growth factor IL-5 activity in vivo, an IL-5 analogue, a nucleic acid fragment encoding it and use in the preparation of an immunogenic composition
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
RU2552929C1 (en) 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Pharmaceutical composition, containing derivatives of glutarimides, and their application for treatment of eosinophilic diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU553017B2 (en) * 1982-06-07 1986-06-26 Chr. Hansen A/S A process for the preparation of chymosin
AU690128B2 (en) * 1993-07-28 1998-04-23 Medvet Science Pty. Ltd. Haemopoietic growth factor antagonists

Also Published As

Publication number Publication date
JP2001511641A (en) 2001-08-14
CA2256368A1 (en) 1997-12-04
WO1997045448A1 (en) 1997-12-04
AUPO005496A0 (en) 1996-06-13
EP0904293A1 (en) 1999-03-31
EP0904293A4 (en) 2002-03-06

Similar Documents

Publication Publication Date Title
ATE402957T1 (en) LOW TOXICITY ANALOGUE OF HUMAN INTERFERON ALPHA
NO942553D0 (en) New Kunitz-type human protease inhibitor and variants thereof
ATE170875T1 (en) HUMAN INSULIN ANALOGUES
DE69535948D1 (en) WDP-40 ABREGING PEPTIDES AND THEIR USE
NZ508352A (en) Hybrid polypeptides with a core therapeutic peptide further characterised with either amino and carboxy terminal linked enhancer or a carboxy terminal linked enhancer
ATE368053T1 (en) ANTIMICROBIAL PEPTIDES
AU6410201A (en) Peptide composition
ATE84547T1 (en) PURIFIED INTERLEUKIN-1.
CY1112839T1 (en) X-CONOXOTINE Peptides having an N-terminal Pyroglutamic Acid
EP0761684A3 (en) Alanine substitution analogues of magainin peptides
WO2004014937A3 (en) Thrombin peptide derivatives
NZ332946A (en) Modified forms of interleukin-5 molecules capable of antagonising of IL-5
GB9917725D0 (en) Peptides
Minchiotti et al. Localization of the amino acid substitution site in a fast migrating variant of human serum albumin
NO971508L (en) Analogs of acidic fibroblast growth factor with increased stability and biological activity
DE3751398D1 (en) Substrate peptides.
NZ290050A (en) Treatment of anxiety with gabapentin
AU2676399A (en) Novel cystine knot protein and materials and methods for making it
WO1999057262A3 (en) Peptide binding to metal ions
IL162133A0 (en) Method of increasing protein expression, proteins and polynucleotides
EP0293130A3 (en) Dimers of parathyroid hormone antagonists
WO1998025955A3 (en) Cloned glucagon-like peptide-2 receptors
WO2001098355A3 (en) Cgi-69 compositions and methods of use
CA2083286A1 (en) Recombinant fibrinogenases, preparation and use thereof
DE69827880D1 (en) IGA1-PROTEASE FRAGMENT AS CARRIER PEPTIDE

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)